tirzepatide head to head semaglutide as Compared with for the Treatment of Obesity First head-to-head trial compares tirzepatide

Screening for pre-existing psychiatric conditions before starting either medication is wise

IM shots work faster but cause more pain

Following the success of the SELECT trial, Wegovy (semaglutide in doses of 1.7 mg and 2.4 mg) received a similar approval in March 2024 for people with overweight or obesity and cardiovascular disease

For example, some brands boast that their mushroom extracts came from the fruiting bodies of the fungi rather than harvesting less-mature spores

We understand that lasting transformation requires addressing multiple aspects of your health

Some patients find that taking semaglutide on the same day each week (if using the weekly injection) allows them to anticipate constipation and time preventive measures accordingly